ai3Bio

ai3Bio is a privately held, preclinical autoimmune-disease biotechnology company developing therapies intended to selectively eliminate pathogenic T helper 17 (Th17) cells in vivo. The company combines artificial-intelligence-enabled analysis of diseased tissue with two therapeutic platforms directed at CD161-positive pathogenic T cells: STARx, an mRNA lipid nanoparticle approach designed to induce targeted cell death, and T Deplete, an antibody-based depletion approach. ai3Bio aims to shift autoimmune treatment from chronic suppression of inflammatory pathways toward a one-step immune-system reset while preserving broader immune function. The company launched on September 29, 2026 with a $48 million Series A financing and operates from Watertown, Massachusetts and Pittsburgh, Pennsylvania.